Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Tolerability of Pelacarsen in Cardiovascular Disease (OLE)
NCT05900141Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Sep 2023
- Primary completion
- Aug 2028
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 3 trial of pelacarsen in Hyperlipoproteinemia a, cardiovascular disease (CVD), sponsored by Novartis. Started Sep 2023; status: active, not recruiting.
02
Drugs
pelacarsen
03
Conditions
Hyperlipoproteinemia acardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT05900141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05900141.